Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin vs Atorvastatin in High Risk Hypercholesterolemia
NCT00683618Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2008
- Primary completion
- Jul 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosuvastatin in hypercholesterolemia (3 arms), sponsored by AstraZeneca. Primary endpoint: Percentage Change From Baseline in Low Density Lipoprotein Cholesterol at 6 weeks. Started May 2008; status: completed.
02
Drugs
rosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00683618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683618.